1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H1, 2016

Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H1, 2016" provides an overview of Zollinger-Ellison Syndrome (Gastrinoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Zollinger-Ellison Syndrome (Gastrinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profile Snapshots 33
Appendix 83
Abbreviations 83
Definitions 83
Research Methodology 84
Secondary Research 84
About GlobalData 85
Contact Us 85
Disclaimer 85
Source 86

List of Tables
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 16
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 20
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 22
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32

List of Figures
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 19
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Zollinger-Ellison Syndrome (Gastrinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32
GlobalData Methodology 84

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Crohn’s disease (CD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.